Propylhexedrine

證據等級: L5

預測適應症: 10 個

Propylhexedrine: From Nasal Congestion to Attention-Deficit/Hyperactivity Disorder (ADHD)

One-Sentence Summary

Propylhexedrine is an indirect-acting sympathomimetic amine traditionally used as an over-the-counter nasal decongestant (e.g., inhaler form for nasal congestion). The TxGNN model predicts it may be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), but currently no clinical trials and no supporting literature exist for this specific drug-indication pair — the prediction rests solely on structural/mechanistic similarity within the knowledge graph.

Quick Overview

Item	Content
Original Indication	Nasal congestion (OTC decongestant; no formal indication record in evidence pack)
Predicted New Indication	Attention-Deficit/Hyperactivity Disorder (ADHD)
TxGNN Prediction Score	99.97%
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, propylhexedrine is an indirect-acting sympathomimetic amine, structurally related to amphetamine, that promotes release of norepinephrine (and to a lesser extent dopamine) from presynaptic nerve terminals. Its traditional OTC use is as a nasal decongestant, exploiting local vasoconstriction (α1-adrenergic effect) rather than central stimulant effects.

The mechanistic rationale for ADHD stems from the fact that ADHD is commonly treated with stimulant medications (e.g., amphetamine, methylphenidate) that act by increasing synaptic norepinephrine and dopamine availability — a mechanism class propylhexedrine shares structurally. However, propylhexedrine has never been studied or approved for CNS/behavioral indications, and its clinical pharmacokinetics, dosing, and CNS penetration for this purpose are not established. This is a knowledge-graph structural-similarity inference (TxGNN score 99.97%, rank 1277) rather than an evidence-based signal — there are zero clinical trials or publications directly linking propylhexedrine to ADHD.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

US Market Information

No license or NDA records are available in the evidence pack. Propylhexedrine’s regulatory status is recorded as Not Marketed, with 0 total licenses on file.

Safety Considerations

Please refer to the package insert for safety information.

Note: Warnings, contraindications, and drug interaction data are currently unavailable (flagged as a Blocking data gap — TFDA label/contraindication data — in the source evidence pack), which prevents completion of a formal initial safety assessment (S1 stage).

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by knowledge-graph structural similarity (Evidence Level L5) with zero clinical trials and zero literature directly linking propylhexedrine to ADHD. Combined with a Blocking-severity data gap on TFDA warnings/contraindications and a High-severity gap on mechanism of action, there is currently insufficient basis to advance this candidate beyond hypothesis stage.

To proceed, the following is needed:

TFDA (or equivalent regulatory) label data — warnings, contraindications — to complete the S1 safety screen
Confirmed mechanism of action (MOA) data from DrugBank or primary literature
Preclinical or pharmacokinetic data establishing CNS bioavailability relevant to ADHD
Identification of any real-world/off-label use signals or case reports as a starting evidence base before considering formal trial design
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.